Investor


investa

Tip’s:Year(2023)…Quick search。

YearOperating revenue(NT$ thousands)Annual increase (decrease) percentage (%)
2024 Total392,635-4.02%
2024/12--
2024/11--
2024/10--
2024/0942,855-4.20%
2024/0841,908-11.09%
2024/0741,613-7,91%
2024/0642,158-10.53%
2024/0544,656-11.81%
2024/0440,086-6.07%
2024/0351,064-2.22%
2023/0232,081-10.50%
2024/0156,21429.20%
2023 Total528,51220.46%
2023/1233,93919.91%
2023/1141,188-4.64%
2023/1044,3201.21%
2023/0944,73620.41%
2023/0847,13621.34%
2023/0745,18714.83%
2023/0647,12223.08%
2023/0550,634
40.90%
2023/0442,67524.66%
2023/0352,22148.46%
2023/0235,84634.82%
2023/0143,50814.79%
2022Total438,7591.04%
2022/1228,303-30.23%
2022/1143,19414.48%
2022/1043,79029.00%
2022/0937,153-5.94%
2022/0838,846-5.55%
2022/0739,3504.79%
2022/0638,28718.41%
2022/0535,936-2.67%
2022/0434,23410.33%
2022/0335,1750.69%
2022/0226,58916.36%
2022/0137,902-17.18%
2021 Total
434,254-8.14%
2021/1240,56565.50%
2021/1137,73051.95%
2021/1033,946-19.39%
2021/0939,498-4.48%
2021/0841,12916.39%
2021/0737,553-16.01%
2021/0632,335-30.28%
2021/0536,920-5.30%
2021/0431,028-19.76%
2021/0334,934-25.63%
2021/0222,851-44.31%
2021/0145,765-4.32%
2020 Total472,7231.50%
2020/1224,511-24.06%
2020/1124,831-36.95%
2020/1042,11422.66%
2020/0941,3515.45%
2020/0835,3386.82%
2020/0744,71018.24%
2020/0646,37825.17%
2020/0538.988-5.75%
2020/0438,6677.78%
2020/0346,97419.24%
2020/0241,02927.57%
2020/0147,832-25.03%
2019 Total465,7562.18%
2019/1232,2782.19%
2019/1139,3834.08%
2019/1034,335-15.23%
2019/0939,2139.71%
2019/0833,082-11.39%
2019/0737,8149.75%
2019/0637,053-0.67%
2019/0541,3683.62%
2019/0435,8755.75%
2019/0339,3935.98%
2019/0232,161-2.76%
2019/0163,80212.04%
2018 Total455,79811.64%
2018/1231,5867.01%
2018/1137,83812.56%
2018/1040,50419.19%
2018/0935,742-4.76%
2018/0837,3354.23%
2018/0734,45512.79%
2018/0637,302-0.23%
2018/0539,9228.20%
2018/0433,9248.77%
2018/0337,1691.60%
2018/0233,07319.40%
2018/0156,94851.70%
2017 Total411,203-0.71%
2017/1229,518-23.12%
2017/1133,61510.25%
2017/1033,9847.76%
2017/0937,5289.37%
2017/0835,782-2.97%
2017/0730,548-26.06%
2017/0637,3882.37%
2017/0536,89517,11%
2017/0431,1901.10%
2017/0336,5845.48%
2017/0227,700-0.69%
2017/0137,5391.95%
2016 Total411,203-13.90%
2016/1238,397-11.13%
2016/1130,490-26.09%
2016/1031,538-27.28%
2016/0934,313-15.35%
2016/0836,876-5.93%
2016/0741,34612.32%
2016/0636,5216.04%
2016/0531,505-17.07%
2016/0430,851-13.25%
2016/0334,683-2.97%
2016/0227,892-22.14%
2016/0136,821-31.41%
2015 Total477,5960.45%
2015/1243,20835.19%
2015/1141,25323.42%
2015/1043,37210.59%
2015/0940,536-0.48%
2015/0839,201-4.93%
2015/0736,783-21.55%
2015/0634,4401.00%
2015/0537,991-19.70%
2015/0435,564-7.86%
2015/0335,745-7.94%
2015/0235,82316.83%
2015/01 53,6802.25%
2014 Total475,45019.75%
2014/1231,96210.89%
2014/1133,4267.98%
2014/1039,21718.71%
2014/0940,73117.73%
2014/0841,23425.64%
2014/0746,88816.22%
2014/0634,09819.51%
2014/0547,30938.36%
2014/0438,59714.80%
2014/0338,82613.07%
2014/0230,66325.75%
2014/0152,49926.81%
2013 Total397,04213.06%
2013/1228,822-3.17%
2013/1130,95627.94%
2013/1033,03737.19%
2013/0934,5976.44%
2013/0832,81815.69%
2013/0740,34536.80%
2013/0628,532-6.51%
2013/0534,1929.32%
2013/0433,62027.22%
2013/0334,3399.74%
2013/0224,384-11.09%
2013/0141,40015.51%
2012 Total351,1875.99%
2012/1229,76521.92%
2012/1124,195-7.01%
2012/1024,08220.55%
2012/0932,50511.42%
2012/0828,3683.32%
2012/0729,4929.59%
2012/0630,5188.70%
2012/0531,277-13.73%
2012/0426,427-0.85%
2012/0331,2902.78%
2012/0227,42727.56%
2012/0135,8414.00%

 

Tip’s:Year(2023)…Quick search。

YearConsolidated financial statementsParent company only financial statements
2023 Download Download

Stock Quotes

Stock Code:4130

GTSM site (TPEx 4130)

 

 

 

 

Dividend Policy

Our dividend policy is formulated based on operational strategies, short, medium, and long-term investment plans, capital budgeting, and changes in internal and external environments. It is aligned with the profitability for the year, and the Board of Directors proposes a distribution plan which is subsequently approved by the shareholders’ meeting. The distribution follows a balanced principle, ensuring that at least fifty percent of the distributable earnings for the year are allocated as dividends to shareholders, with a minimum of ten percent in cash dividends.

 

Historical Dividends

 

Year

Shareholders’ Meeting Date

Dividend per Share

(Common Stock)

Ex-Rights Date

Ex-Dividend Date

Dividend Payment Date

Cash Dividend

 

Stock Dividend

 

2023

2024/05/31

0.150

0.3

2024/08/21

2024/08/21

2024/09/25

2022

05/29/2023

0.175

0

07/14/2023

07/14/2023

08/04/2023

2021

05/31/2022

0.35

0

07/26/2022

07/26/2022

08/18/2022

2020

8/10/2021

0.41

0.2

9/18/2021

9/18/2021

10/15/2021

2019

5/29/2020

0.465

0.2

8/31/2020

8/31/2020

9/28/2020

2018

5/30/2019

0.5

0.3

7/23/2019

7/23/2019

8/21/2019

2017

5/30/2018

0.8

0

 –

7/12/2018

8/3/2018

2016

6/23/2017

0.3522

0

 –

8/2/2017

8/25/2017

2015

5/30/2016

0.5

0

 –

7/12/2016

8/5/2016

2014

6/2/2015

0.5

0

7/13/2015

7/31/2015

2013

6/10/2014

0.3

0

7/18/2014

8/4/2014

2012

6/24/2013

0.3

0

7/16/2013

8/6/2013

Shareholders Meeting

Date

Meeting Notice

Agenda Handbook

Annual Report

Meeting Minutes

2024/05/31

Download

Download

Download

Download

2023/05/29

Download

Download

Download

Download

 

 

Shareholders Meeting Video Materials

Shareholders’ Meeting Date

Video

2024/05/31

Click(外部連結)

2023/05/29

Click(外部連結)

Stock Transfer Agent

Name:

Capital Securities Corporation

Address:

B2F., No.97, Sec. 2, Dunhua S. Rd., Da’an Dist., Taipei

Tel:

(02)2702-3999

Website:

http://www.capital.com.tw/

 

Corporate Governance Organizational Structure

 

Sorry, this entry is only available in 繁中.

In “Procedures for Election of Directors and Supervisors,” the company clearly stipulates the principle of diversification of the board of directors, strengthens corporate governance, and promotes the sound development of the board’s composition and structure. Directors are elected and nominated through a candidate nomination system. After the board of directors passes the resolution, they are submitted to the shareholders’ meeting for selection. To formulate an appropriate diversification policy based on its own operations, business model, and development requirements, it should include, but not be limited to, the two major aspects of the standard listed below:

(i) Fundamental qualities and values: gender, age, nationality, and culture, etc.

(ii) Professional knowledge and abilities: professional background (such as law, accounting, industry, finance, marketing, or technology), professional skills, industrial experience, business management, an international perspective, management and decision-making skills, etc.

Board Member

Title

Name

Experience (Education)

Other Position

Chairman

Chen, Jen

.Ph.D. in Chemistry, University of Rochester, USA

.Novartis Program Host

.Genelabs, Vice Chairman of Asia Sales

.QPS-Qualitix Clinical Research Co., Ltd., Chairman

.Bio Taiwan Committee (BTC), Executive Yuan, Committee Member

.Genovate Biotechnology Co., Ltd., Chairman and CSO

.Quest Pharmaceutical Services Taiwan Co., Ltd., Corporate Representative (Director)                     

.Genovate Biotechnology (Cayman) Co., Ltd., Corporate Representative (Director)

.Unipharma Co. Ltd., Chairman and CSO

.Reber Genetics Co., Ltd., Corporate Representative (Director)

.NaviFUS Corporation, corporate representative (Chairman) and CSO

.Genovate NaviFus (Australia)Pty. Ltd.,  Corporate Representative (Director)

.Savior Lifetec Corporation, Corporate Representative (Director)

Director

Chen, Hsiu-Hui

.Ph.D. Department of Agricultural Chemistry, NTU

.Head of CEO Office and Planning and Examination Office, Research Fellow of R&D Division, Development Center for Biotechnology

.Research Fellow, Yi Cheng Biotech

.Postdoctoral Fellow, Academia Sinica

.Associate Executive Officer, Development Center for Biotechnology

.Corporate Representative (Director), EirGenix Inc.

Director

Huang, Chi-Ying

.Ph.D. Department of Biochemistry, Biophysics, Iowa State University

.Director, PharmaEngine Inc.

.Associate Research Fellow, National Health Research Institutes

.Postdoctoral Fellow, Dept. of Chemical & Systems Biology, Stanford University

.Distinguished Professor and Director, Department of Pharmacy, National Yang Ming Chiao Tung University

.Associate Director, Department of Pharmacy, National Yang Ming Chiao Tung University

.Director, Chong Hin Loon Memorial Cancer and Biotherapy Research Center, National Yang Ming Chiao Tung University

.Jointly-Appointed Professor, Department of Biochemistry, Kaohsiung Medical University

.Corporate Representative (Director), Intech Biopharm. Ltd.

Director

Chu, Chia-Chen

.Master’s Degree, Science in Health Policy and Management, Harvard University

.Ministry of Health and Welfare, Associate Researcher

.Genovate Biotechnology Co., Ltd., Director of International Affairs

.Genovate Biotechnology Co., Ltd., New Drug Development Department, Vice President

.Genovate Biotechnology Co., Ltd., General Manager

.Unipharma Co. Ltd., Corporate Representative (Director)

.NaviFUS Corporation, Corporate Representative (Director)

.Genovate NaviFus Inc., Corporate Representative (Director)

.Genovate NaviFus (Australia)Pty.Ltd., Corporate Representative (Director)

Independent Director

Lee, Shih-Jen

.Ph.D. in Chemistry, University of South Carolina

.Easywell Biomedicals, Inc., Chairman

.Haoli Biotechnology Management Consulting Co., Ltd., Managing Director

.Heyu Management Consulting Co., Ltd., Investment Director

.Silver Biotech Management, Inc. Managing Director

.China Development Industrial Bank Senior Associate of Investment Department

.TAHO Pharmaceuticals Ltd., Chairman

.Easywell Biomedicals, Inc., Chairman

.Sunko Ink Co., Ltd., Independent Director

.Transwell Biotech Co., Ltd., Director

.Industrial Technology Investment Co., Ltd., Director

.Taimed Biologics Inc., Independent Director

.OBI Pharma Inc., Independent Director

.Amphastar Pharmaceuticals, Inc., Director

.Amphastar Pharmaceuticals, Inc., Director

Independent Director

Liu, Ke-Yi

.Ph.D. in Accounting, Xiamen University

.Master of Accounting, University of Illinois

.Bachelor of Finance and Taxation, National Chengchi University

.BDO Taiwan Joint Venture Accountant

.First Commercial Bank Corporate Representative (Supervisor)

.Independent Director, Taiwan Cooperative Financial Holding Co., Ltd.

Independent Director

Chang, Chin-Ming

.Ph.D. in Pharmacy, University of Texas at Austin

.Graduated in Department of Pharmacy, National Taiwan University

.Senior Executive in Pharmaceuticals, Processing and R&D, Allergan Inc.

.Senior Research Fellow, Eli Lilly & Company

.CEO, TaiMed Biologics

.Director, Biotheravision Inc.

.Director, Oukejian Biomedical Technology Co., Ltd.

Independent Director

Su, Lai-Shou

.M.B.A. of University of North Texas, U.S.A.

.Executive Secretary of National Development Fund

.Board Director of Oversea-Chinese Banking Corporation

.Board Director of HanTech Venture Capital Corporation

.Board Director of Taiwan Aerospace Corporation

.Supervisor of Kaohsiung Rapid Transit Corporation

.Supervisor of Powerchip Semiconductor Corporation

.Supervisor of Mirle Automation Corporation

.Vanguard International Semiconductor Corporation, Corporate Representative (Director)

.Taiwan Bio-Manufacturing Corporation, Corporate Representative (Director)

 

Audit Committee

Genovate established the Audit Committee in June 2017. The Audit Committee is responsible for the following duties and shall submit its recommendations to the Board of Directors for discussion:

  1. Formulating or amending internal control systems in accordance with Article 14-1 of the Securities and Exchange Act.

  2. Assessing the effectiveness of internal control systems.

  3. Establishing or amending procedures for significant financial transactions involving acquisition or disposal of assets, derivative transactions, loans of funds to others, endorsement for others, or provision of guarantees in accordance with Article 36-1 of the Securities and Exchange Act.

  4. Matters involving conflicts of interest of directors themselves.

  5. Significant asset or derivative transactions.

  6. Significant loans of funds, endorsements, or guarantees.

  7. Offering, issuance, or private placement of equity securities.

  8. Appointment, dismissal, or compensation of chartered public accountants (CPA).

  9. Appointment or removal of heads of finance, accounting, or internal audit.

  10. Quarterly and annual financial reports.

  11. Other significant matters as required by other companies or competent authorities.

Please refer to Genovate Annual Report for the relevant year for the number of meetings convened and each member’s attendance rate.

Remuneration Committee

The Board of Directors has established the Remuneration Committee in accordance with the Securities and Exchange Act of the Republic of China. As per the regulations, the Remuneration Committee must include at least one independent director as defined by the Securities and Exchange Act. The Remuneration Committee currently consists of three members, all of whom are independent directors.

In accordance with the organizational regulations approved by the Board of Directors, the Remuneration Committee is responsible for establishing and reviewing policies, systems, standards, and structures related to the evaluation of the performance and compensation of directors and executives. The committee also evaluates the remuneration of directors and executives.

The Remuneration Committee convenes regular meetings at least twice a year.

Please refer to Genovate Annual Report for the relevant year for the number of meetings convened and each member’s attendance rate.

Committee Member

Name

Remuneration Committee

Audit Committee

Independent Director

Lee, Shih-Jen

V

(convener)

V

Independent Director

Liu, Ke-Yi

V

V

(convener)

Independent Director

Chang, Chin-Ming

V

V

Independent Director

Su, Lai-Shou

V

V

 

Internal Audit Organization and Operation

1.Purpose of Internal Audit:

The purpose of internal audit is to assess and examine the effectiveness of internal control systems, the reliability of reporting, compliance with relevant regulations, and to assist the board of directors and management in identifying deficiencies in internal control systems and measuring operational effectiveness and efficiency. It aims to provide timely recommendations to ensure continuous effective implementation of internal control systems and serve as a basis for reviewing and revising these systems.

 

2.Internal Audit Organization:

The company has established an independent internal audit unit reporting to the board of directors, headed by a Chief Internal Auditor who attends board meetings to report on audit activities. Apart from the appointment and dismissal of the Chief Internal Auditor, which requires approval from the Audit Committee and resolution by the board of directors, other matters such as appointment, evaluation, and compensation of internal audit personnel follow the company’s human resources management procedures, performance assessment methods, and employee compensation distribution rules. These are signed off by the Chief Internal Auditor and approved by the Chairman of the Board. Performance assessments for audit personnel follow the same procedures as for regular employees, involving self-assessment, initial review by the Chief Internal Auditor, and final decision by the Chairman of the Board.

 

3.Explanation of Internal Audit Operations:

 

4.Audit Scope: Internal audit activities include examining and evaluating the effectiveness of the internal control system design and execution in various units and subsidiaries of the company.

 

5.Audit Targets: Audit targets encompass all business responsibilities of the company’s units and subsidiaries.

 

6.Audit Procedures:

(a)

Annual audit plan: A draft of the annual audit plan is prepared before the end of each year and executed after approval by the board of directors.

(b)

Conducting audit operations: Audits are conducted according to the approved annual audit plan or as per directives from the company’s board of directors or management, specific projects, or business needs.

(c)

Self-inspection operations: Supervising each internal unit and subsidiary to conduct an annual self-inspection of their internal control systems and reviewing their self-inspection reports.

  1. Submission and Reporting of Audit Reports:

(a)

After the audit report and follow-up report are reviewed and confirmed, they are submitted for inspection by relevant supervisory authorities by the end of the month following the completion of audit items.

(b)

In case of discovering significant violations or potential significant damage to the company during audit operations, immediate reporting and notification to relevant supervisory authorities are required.

(c)

If there are deficiencies in audit reports, relevant units are requested to cooperate in improvement efforts.

  1. Implementation Status of Corrective Actions:

Internal audit personnel regularly prepare follow-up reports on identified deficiencies and anomalies in the internal control system to ensure that appropriate corrective measures have been taken by the relevant units.

  1. External Reporting Operations:

In accordance with the “Guidelines for Establishing Internal Control Systems for Publicly Issued Companies,” all required reporting and record-keeping operations are conducted within specified deadlines using the designated internet information system format.

Major Company Policies

1.Articles of Incorporation.

Download

2.Operating procedures of endorsement / guarantees.

Download

3.Regulations Governing Loaning of Funds.

Download

4.Regulations Governing the Acquisition and Disposal of Assets.

Download

5.Procedure for Meetings of Board of Directors.

Download

6.Procedure for Shareholders Meetings.

Download

7.Procedures for Election of Directors.

Download

8.Rules Governing the Scope of Powers of Independent Directors.

Download

9.Rules Governing the Scope of Powers of Independent Directors.

Download

10.Ethical Corporate Management Best Practice Principles.

Download

11.Remuneration Committee Charter.

Download

12.Procedures for Handling Material Inside Information and the Prevention of Insider Trading.

Download

13.Measures for the Report on Illegal, Immoral and Dishonest Acts.

  Download

14.Procedures for Ethical Management and Guidelines for Conduct.

  Download

15.Audit Committee Charter.

  Download

16.Rules for Performance Evaluation of Board of Directors and Functional Committees.

  Download

17.Corporate Governance Best Practice Principles.

  Download

Investor Conference

Company Name/Code:4130

MOPS (Material Information /Investor Conference)

 

Material Information

By Stock Code:4130

MOPS (Material Information /Advanced Search)

Investor Relations & Media Contact

Spokesperson:

Name

Chiang, Wei-Min

Title

Senior Director, Administration Division

Tel

02-23211978#2631

Email

williechiang@genovate-bio.com

Acting Spokesperson:

Name

Lin, Hui-Ling

Title

Vice President, Finance

Tel

03-5982221#116

Email

annlin@genovate-bio.com

Stock Transfer Agent: 

Name

Capital Securities Corporation

Stock Affair Specialist

Ms. Chen

Tel

(02)2702-3999

Email

a33404@capital.com.tw